Strategic transactions and agreements - Morphimmune - Fair values of assets acquired and liabilities - (Details) - USD ($) $ in Thousands	Oct. 02, 2023	Dec. 31, 2024	Dec. 31, 2023
Assets acquired:
Cash and cash equivalents		$ 143,351	$ 98,679
Prepaid expenses and other current assets		4,036	6,561
Property and equipment		10,113	2,073
Total assets		240,241	148,540
Liabilities assumed:
Accrued expenses		33,177	8,025
Total liabilities		$ 59,076	$ 28,658
Morphimmune Inc
Asset acquisitions
Common stock issued	$ 72,453
Share-based equity awards allocated to consideration paid	14,708
Transaction costs	792
Consideration paid	87,953
Assets acquired:
Cash and cash equivalents	10,068
Prepaid expenses and other current assets	191
Property and equipment	646
In-process research and development	80,802
Total assets	91,707
Liabilities assumed:
Accounts payable	1,147
Accrued expenses	2,607
Total liabilities	3,754
Net assets acquired	$ 87,953